TROXYCA ER
Drug
PFIZER INC.
Total Payments
$529,625
Transactions
90
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $18,485 | 3 | 1 |
| 2018 | $460,164 | 79 | 3 |
| 2017 | $50,976 | 8 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $459,364 | 77 | 86.7% |
| Consulting Fee | $45,362 | 5 | 8.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,900 | 8 | 4.7% |
Payments by Type
Research
$459,364
77 transactions
General
$70,262
13 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPENLABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ALO02 OXYCODONE HYDROCHLORIDE AND NALTREXONE HYDROCHLORIDE EXTENDEDRELEASE CAPSULES IN CHILDREN AND ADOLESCENTS 717 YEARS OF AGE WHO REQUIRE OPIOID ANALGESIA | PFIZER INC. | $155,103 | 0 |
| FULL USING CLAIMS DATA TO DEFINE OPIOID MISUSE AND ABUSE | PFIZER INC. | $110,111 | 0 |
| IQVIA DAATA STRATIFIED ACCORDING TO THE REQUESTED AGE BANDS AQND AAPCC NPDS HEROIN DATA THROUGH 4TH QUARTER 2017 | PFIZER INC. | $94,961 | 0 |
| FULL MAXIMIZING OUTCOMES AND SAFETY OF LONGTERM OPIOID THERAPY IN CHRONIC NONCANCER PAIN CLINICIAN ADHERENCE TO EVIDENCEBASED TREATMENT GUIDELINES AND ITS DETERMINANTS | PFIZER INC. | $48,347 | 0 |
| SURVEILLANCE OF PRESCRIPTION DRUG ABUSE IN CANADA A PILOT STUDY | PFIZER INC. | $43,343 | 0 |
| PROVIDER SHALL PROVIDE PFIZER WITH ONGOING SURVEILLANCE TO CONTINUALLY MONITOR THE ABUSE MISUE AND DIVERSION OF EMBEDA AND OTHER RELEVANT PRESCRIPTION OPIOIDS AND HEROIN | PFIZER INC. | $7,500 | 0 |
Top Doctors Receiving Payments for TROXYCA ER
Ad
Manufacturing Companies
- PFIZER INC. $529,625
Product Information
- Type Drug
- Total Payments $529,625
- Total Doctors 5
- Transactions 90
About TROXYCA ER
TROXYCA ER is a drug associated with $529,625 in payments to 5 healthcare providers, recorded across 90 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2019. In 2019, $18,485 was paid across 3 transactions to 1 doctors.
The most common payment nature for TROXYCA ER is "Unspecified" ($459,364, 86.7% of total).
TROXYCA ER is associated with 6 research studies, including "AN OPENLABEL STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ALO02 OXYCODONE HYDROCHLORIDE AND NALTREXONE HYDROCHLORIDE EXTENDEDRELEASE CAPSULES IN CHILDREN AND ADOLESCENTS 717 YEARS OF AGE WHO REQUIRE OPIOID ANALGESIA" ($155,103).